Treace Medical Concepts, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Treace Medical Concepts, Inc. (TMCI) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $12.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-27
- Treace Medical Concepts, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2021-12-31 was $8.40M, a 189.66% increase year-over-year.
- Treace Medical Concepts, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2021-09-30 was -$2.00M.
- Treace Medical Concepts, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2021-06-30 was $0.00.
- Treace Medical Concepts, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2021-03-31 was $500.00K, a 44.44% decline year-over-year.
- Treace Medical Concepts, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $12.50M, a 40.45% increase from fiscal 2024.
- Treace Medical Concepts, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $8.90M, a 27.64% decline from fiscal 2023.
- Treace Medical Concepts, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $12.30M, a 12.84% increase from fiscal 2022.
- Treace Medical Concepts, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $10.90M, a 70.31% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 9 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|---|---|---|
| 2025-12-31 | $12.50M 10-K · filed 2026-02-27 | |||
| 2024-12-31 | $8.90M 10-K · filed 2026-02-27 | |||
| 2023-12-31 | $12.30M 10-K · filed 2025-02-27 | |||
| 2022-12-31 | $10.90M 10-K · filed 2024-02-27 | |||
| 2021-12-31 | $8.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $6.40M derived: sum of 2 quarters · filed 2023-03-08 | $6.40M derived: sum of 3 quarters · filed 2023-03-08 | $6.40M 10-K · filed 2023-03-08 |
| 2021-09-30 | -$2.00M 10-Q · filed 2021-11-04 | -$2.00M derived: sum of 2 quarters · filed 2021-11-04 | -$2.00M 10-Q · filed 2021-11-04 | $1.40M derived: sum of 4 quarters · filed 2022-03-04 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | $3.40M derived: sum of 3 quarters · filed 2022-03-04 | $1.40M derived: sum of 4 quarters · filed 2022-03-04 |
| 2021-03-31 | $500.00K 10-Q · filed 2021-05-25 | $3.40M derived: sum of 2 quarters · filed 2022-03-04 | $1.40M derived: sum of 3 quarters · filed 2022-03-04 | $1.40M derived: sum of 4 quarters · filed 2022-03-04 |
| 2020-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-04 | $900.00K derived: sum of 2 quarters · filed 2022-03-04 | $900.00K derived: sum of 3 quarters · filed 2022-03-04 | $900.00K 10-K · filed 2022-03-04 |
| 2020-09-30 | -$2.00M 10-Q · filed 2021-11-04 | -$2.00M derived: sum of 2 quarters · filed 2021-11-04 | -$2.00M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $900.00K 10-Q · filed 2021-05-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |